QUECTEL-WIRELESS
27.3.2024 14:01:35 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has made further additions to its comprehensive range of antennas for IoT devices and deployments. The latest launches include the YEMN016AA and YEMN017AA 5G 5-in-1 combination antennas, the YECN001J1A and YECT000WBA external 5G antennas and the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas.
“We are thrilled to expand our product line with antennas that offer superior performance and meet the unique needs of our IoT customers,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Quectel consistently enhances its diverse portfolio to precisely address the unique requirements of our clients' deployments and applications, offering unparalleled performance and adaptability, and these antennas add to that portfolio.”
The YEMN016AA is a 5G and global navigation satellite systems (GNSS) 5-in-1 antenna measuring 204.4mm x 86.7mm x 32mm. This ultra-wide-band 5G/4G antenna provides broad coverage from 600–6,000MHz whilst offering backward-compatibility to support 3G and 2G networks as well as LTE Cat-M and narrowband IoT (NB-IoT). The antenna is available with connection via five cable lengths from 300–5,000 mm, terminated with SMA connectors. This low profile, screw mount omnidirectional antenna, ideal for applications where the antenna is required to be discrete, is easy to install with maximum durability assured thanks to its IP69K PC KIBILAC® ASA enclosure. It is compatible with Quectel's RM520x Series modules.
The Quectel YEMN017AA is a 5G screw mount 5-in-1 antenna puck optimized for 5G and 4G networks. With a diameter of 103.5mm and height of 42.5mm, the antenna can integrate a variety of antennas, such as 5G, 4G, GNSS and Wi-Fi antennas. Available with multiple mounting options including screw, pole, wall, magnetic, adhesive and others, the antenna box supports multiple connector types and cable lengths and is designed to offer a more flexible and reliable high-performance antenna for outdoor applications.
Quectel has also added the YECN001J1A and YECT000WBA external 5G antennas to its portfolio. Both antennas cover the 5G NR Sub-6 GHz frequency bands and are compatible with 4G, 3G, 2G and LPWA bands. Featuring high efficiency and gain, both offer an ideal omni-directional antenna solution to ensure high-speed data transmission. Ideal for a diversity of wireless communication devices such as routers, outdoor equipment and real-time monitoring equipment, the antennas feature a diameter of 40.6mm and height of 104mm. The antennas are both RoHS and REACH compliant and Quectel offers flexible installation with custom cable length and connector options.
For users prioritizing GNSS, Quectel has introduced the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas. Operating in the 1164-1189MHz and 1559-1606MHz frequency bands these antennas measure 62mm x 56mm x 23mm. The antennas support different installation or connection methods such as screw mount, adhesive mount, magnetic mount, internal cable, and external SMA. Customized connector types and cable lengths are provided according to requirements.
In common with all Quectel antennas, Quectel provides comprehensive antenna design support such as simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. In addition, Quectel antennas can be pre-integrated with Quectel’s vast range of modules.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327795741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom